
References
Akira K, Taira T, Hasegawa H, et al. (1998). Studies on the stereoselective internal acyl migration of
ketoprofen glucuronides using 13C labeling and nuclear magnetic resonance spectroscopy. Drug
Metab Dispos 26:457–64.
Asaki T, Kuwano K, Morrison K, et al. (2015). Selexipag: an oral and selective IP prostacyclin
receptor agonist for the treatment of pulmonary arterial hypertension. J Med Chem 58:7128–37.
Bruderer S, Hurst N, Kaufmann P, et al. (2014). Multiple-dose up-titration study to evaluate the
safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available
selective prostacyclin receptor agonist, in healthy subjects. Pharmacology 94:148–56.
Dubois N, Lapicque F, Maurice MH, et al. (1993). In vitro irreversible binding of ketoprofen
glucuronide to plasma proteins. Drug Metab Dispos 21:617–23.
Gnerre C, Segrestaa J, Seeland S, et al. (2017). The metabolism and drug-drug interaction potential
of the selective prostacyclin receptor agonist selexipag. Xenobiotica
doi:10.1080/00498254.2017.1357088
Ichikawa T, Yamada T, Treiber A, et al. (2018). Pharmacokinetics of the selective prostacyclin
receptor agonist selexipag in rats, dogs, and monkeys. Xenobiotica 48:186–96.
Kaufmann P, Okubo K, Sidharta PN, et al. (2012). Investigation of the absorption, metabolism, and
excretion of 14C-selexipag following oral administration to healthy male subjects. Clin Pharmacol
Ther 91(suppl. 1):S85.
Kaufmann P, Niglis S, Bruderer S, et al. (2015). Effect of lopinavir/ritonavir on the
pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in
healthy subjects. Br J Clin Pharmacol 80:670–7.
Kaufmann P, Hurst N, Astuc B, Dingemanse J. (2017). Absolute oral bioavailability of selexipag, a
novel oral prostacyclin IP receptor agonist. Eur J Clin Pharmacol 73:151–6.
Kretz-Rommel A, Boelsterli UA. (1994). Mechanism of covalent adduct formation of diclofenac to
rat hepatic microsomal proteins: Retention of the glucuronic acid moiety in the adduct. Drug Metab
Dispos 22:956–61.
Kuwano K, Hashino A, Asaki T, et al. (2007).
2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304),
an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther
322:1181–8.
Li B, Sedlacek M, Manoharan I, et al. (2005). Butyrylcholinesterase, paraoxonase, and albumin
esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673–84.
Nakamura A, Yamada T, Asaki T (2007). Synthesis and evaluation of N-acylsulfonamide and
N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist. Bioorg Med Chem 15:7720–5.
Presle N, Lapicque F, Fournel-Gigleux S, et al. (1996). stereoselective irreversible binding of
Accepted Manuscript